---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-001518"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:48:51.416115+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics appoints Cedric O'Gorman MD as Chief Medical Officer

## Summary
- Dr. O'Gorman appointed CMO effective January 9, 2023, leading medical, clinical, and regulatory for REL-1017 MDD program.
- He brings over 20 years CNS experience; previously CMO at Alpha Cognition and SVP at Axsome Therapeutics.
- CEO cites his expertise with similar-mechanism antidepressants and key regulatory discussions ahead.
- Corporate presentation updated and filed as Exhibit 99.2.

## SEC filing metadata
- accession: 0001213900-23-001518
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023001518/0001213900-23-001518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023001518/ea171401-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-001518
- JSON: https://secwatch.observer/filing/0001213900-23-001518.json
- Plain text: https://secwatch.observer/filing/0001213900-23-001518.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.